Slide Striving to unleash the potential of mTOR inhibition using precision medicine and nanoparticle albumin technology At Aadi Bioscience, our mission is to dramatically improve the lives of people with mTOR-driven diseases. We believe success depends on improving upon current mTOR inhibitors and leveraging the latest genomic profiling technology to identify the patients most likely to benefit from mTOR inhibition.

Our Approach:

Identify diseases with mTOR pathway driver mutations and strong evidence of mTOR involvement in pathology of disease

Target genomically defined subgroups across cancer types with mTOR pathway aberrations including TSC1, TSC2, and PTEN who are most likely to respond to mTOR treatment

Treat patients with nab-sirolimus (ABI-009), a potential best-in-class mTOR inhibitor leveraging the proven albumin-bound platform